3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
3
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
62
Rectal Neoplasms
49
Breast Neoplasms
48
Stomach Neoplasms
37
Esophageal Neoplasms
35
Colorectal Neoplasms
33
Lung Neoplasms
30
Squamous Cell Carcinoma of Head and Neck
28
Pancreatic Neoplasms
25
Brain Neoplasms
25
Glioblastoma
23
Neoplasms
22
Sarcoma
21
Neoplasm Metastasis
20
Carcinoma, Hepatocellular
18
Head and Neck Neoplasms
17
Glioma
16
Esophageal Squamous Cell Carcinoma
16
Colonic Neoplasms
13
Recurrence
11
Ovarian Neoplasms
10
Oropharyngeal Neoplasms
10
Melanoma
10
Astrocytoma
10
Adenocarcinoma Of Esophagus
10
Thyroid Neoplasms
9
Hypopharyngeal Neoplasms
9
Prostatic Neoplasms
8
Laryngeal Neoplasms
8
Central Nervous System Neoplasms
8
Interventions
pembrolizumab
7
Paclitaxel
4
Cisplatin
3
Carboplatin
3
camrelizumab
2
Radiotherapy
2
Radiosurgery
2
Nivolumab
2
Immunotherapy
2
Immune Checkpoint Inhibitors
2
tremelimumab
1
toripalimab
1
spartalizumab
1
sinoporphyrin sodium
1
poly ICLC
1
penpulimab
1
durvalumab
1
avelumab
1
Tramadol
1
Tadalafil
1
Surgical Procedures, Operative
1
S 1 (combination)
1
Radiation
1
Poly(ADP-ribose) Polymerase Inhibitors
1
Photochemotherapy
1
Pemetrexed
1
Oxaliplatin
1
Morphine
1
Leucovorin
1
Injections
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Surgical Procedures, Operative
×
Clear all
NCT03116529
2024-11-04
NEXIS
University of Maryland, Baltimore
Phase 1/2
Terminated
22 enrolled